Article Type
Changed
Fri, 01/04/2019 - 11:09
Display Headline
The importance of hematologic, cytogenetic, and molecular testing and mutational analysis in chronic myeloid leukemia

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has made it possible for this cancer to be controlled in many patients for long periods with chronic medication and regular monitoring of disease status. Hematologic and cytogenetic testing, molecular monitoring, and BCR-ABL1 mutational analysis have become integral to the routine management of CML. The information that each type of test provides is essential to confirm a diagnosis, determine the disease stage, assess response to treatment, and monitor for signals of disease progression – all of which can be used to identify patients who might require further evaluation, closer follow-up, and additional intervention, and to guide clinical decisions.


Click on the PDF icon at the top of this introduction to read the full article.
 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 12(5)
Publications
Topics
Page Number
179-187
Legacy Keywords
chronic myeloid leukemia, CML, BCR-ABL1, tyrosine kinase inhibitors, TKI
Sections
Article PDF
Article PDF

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has made it possible for this cancer to be controlled in many patients for long periods with chronic medication and regular monitoring of disease status. Hematologic and cytogenetic testing, molecular monitoring, and BCR-ABL1 mutational analysis have become integral to the routine management of CML. The information that each type of test provides is essential to confirm a diagnosis, determine the disease stage, assess response to treatment, and monitor for signals of disease progression – all of which can be used to identify patients who might require further evaluation, closer follow-up, and additional intervention, and to guide clinical decisions.


Click on the PDF icon at the top of this introduction to read the full article.
 

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has made it possible for this cancer to be controlled in many patients for long periods with chronic medication and regular monitoring of disease status. Hematologic and cytogenetic testing, molecular monitoring, and BCR-ABL1 mutational analysis have become integral to the routine management of CML. The information that each type of test provides is essential to confirm a diagnosis, determine the disease stage, assess response to treatment, and monitor for signals of disease progression – all of which can be used to identify patients who might require further evaluation, closer follow-up, and additional intervention, and to guide clinical decisions.


Click on the PDF icon at the top of this introduction to read the full article.
 

Issue
The Journal of Community and Supportive Oncology - 12(5)
Issue
The Journal of Community and Supportive Oncology - 12(5)
Page Number
179-187
Page Number
179-187
Publications
Publications
Topics
Article Type
Display Headline
The importance of hematologic, cytogenetic, and molecular testing and mutational analysis in chronic myeloid leukemia
Display Headline
The importance of hematologic, cytogenetic, and molecular testing and mutational analysis in chronic myeloid leukemia
Legacy Keywords
chronic myeloid leukemia, CML, BCR-ABL1, tyrosine kinase inhibitors, TKI
Legacy Keywords
chronic myeloid leukemia, CML, BCR-ABL1, tyrosine kinase inhibitors, TKI
Sections
Citation Override
JCSO 2014;12(5):179-187
Disallow All Ads
Alternative CME
Article PDF Media